Jason A. Leverone
CIK 1692747 · Chief Financial Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$75.0K
Companies
3
Total Filings
19
Lifetime Open-Market Net
-$14.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Chief Financial Officer | 18,802 | $3.99 | $75.0K | -$14.2K | 9 | 2026-06-24 |
| VRDN | Chief Financial Officer | — | $23.37 | — | $0 | 1 | 2021-01-20 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | CFO, Treasurer & Secretary | 48,829 | — | — | $0 | 9 | 2020-03-17 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-17 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Exer (M) | +11,249 | $6.4K | EDGAR |
| 2020-02-14 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-08-23 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Exer (M) | +3,093 | $1.8K | EDGAR |
| 2019-02-08 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-08-22 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | — | — | $0 | EDGAR |
| 2018-08-09 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Exer (M) | +29,530 | $16.8K | EDGAR |
| 2018-02-22 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | — | — | $0 | EDGAR |
| 2018-02-02 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-16 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.